GBI research: the Asia Pacific hypertension market will reach 20 billion US dollars in 2021

Source: hypertention (2015-7-27) is a chronic disease characterized by the continuous increase of arterial blood pressure, which often causes diseases of heart, brain, kidney and other important organs with corresponding consequences It is estimated that in 2014, the total number of hypertension patients in four countries (China, India, Australia, Japan) in the Asia Pacific region (APAC) reached 517 million In the next six years (2015-2021), this number will grow at a CAGR of 1.2%, reaching 561 million by 2021 High prevalence rate is a major contribution to medical expenses and a major cause of high incidence rate However, doctors, patients and the public have low awareness of hypertension, which also leads to poor blood pressure control Recently, GBI research, a well-known global market research company, released a research report, pointing out that in the next six years (2015-2021), the market of hypertension treatment in four countries in the Asia Pacific region (APAC) (China, India, Australia, Japan) will grow steadily with an annual CAGR of 3.4%, reaching US $19.9 billion by 2021, and the market value of the market in 2014 will be 157 Billion dollars The report points out that this moderate increase is mainly due to the lack of hypertension cognition, leading to a lower diagnosis rate and treatment rate In the Asia Pacific hypertension treatment market, Japan has the largest market share, accounting for 52% in 2014, with a market value of US $8.1 billion Compared with China and India, the annual cost of treatment (Acot) in Japan is significantly higher than that in the former two groups, although the number of patients in Japan is small However, in the next six years (2015-2021), the growth rate of Japanese market is the lowest in the Asia Pacific region, CAGR is only 1%, and the market value reaches 8.7 billion US dollars in 2021, which is partly due to the patent expiration of Novartis antihypertensive drug rasilez (aliskiren, aliskiren) in 2015, and olmetec (olmesartan medoxomi, olmesartan ester) in 2016 The patent expires in According to the report, in the next six years, India's hypertension treatment market will grow fastest, with CAGR reaching 12.6% Its market value in 2014 is only $800 million, and it will reach $1.9 billion by 2021 In addition, the annual treatment cost (Acot) of hypertension treatment in India is very low among the four countries in Asia Pacific, which is less than one tenth of that in Japan During the forecast period, the aging of population and other risk factors (such as obesity, inactivity, drinking) in India will increase, leading to an increase in the incidence rate of hypertension This, in turn, will boost demand for therapeutic drugs and drive the country's high-speed growth in the hypertension treatment market.